HSV infection, with its epidemiological magnitude and physical and psychological effects on the affected, is a major public health issue.
The WHO estimated that nearly 70% of the global population aged 15-49 has either HSV-1, HSV-2, or both. This is possible through a unique mechanism in which the virus establishes itself in the host organism (humans): once an infection is established, HSV then initiates lifelong latent infections in the human neuronal cells and lays dormant for the majority of its life cycle.
While HSV is an insidious yet ubiquitous virus that has rendered the biotech and medical communities defenseless for over a century, this group of therapeutic herpes vaccines is expected to provide a functional cure for patients who suffer from HSV-1 and HSV-2 infections.
ABC believes in tackling the subset of Human Herpes Virus (HSV-1)with the only live-attenuated HSV vaccine there is in development.
This vaccine is similar to the ideology behind Zostavax, a live-attenuated Shingles vaccine that had been used successfully to vaccinate against Varicella Zoster Virus (HHV-3) for many decades.
Both of the live-attenuated HSV-1 and HSV-2 therapeutics were under research and development at Southern Illinois University in the US for almost 20 years, and have been proven in published academic studies to be 50x more effective than subunit D vaccines, the leading vaccine candidates in the industry.
The primary investigators successfully completed and replicated numerous animal model studies that demonstrated safety and immunogenicity.
*Note: For complete description of therapeutics and diagnostics with citations, please refer to ABC ICO Prospectus